HASBROUCK HEIGHTS, N.J., June 12, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the first patient enrolment for Study NX03-0040, the Company’s Phase 2 Study of NX-1207 for low risk localized prostate cancer. NX-1207 is also in Phase 3 development in the U.S. and Europe for benign prostatic hyperplasia (BPH).
